Journal of Clinical OncologyTBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes

Olaparib, a PARP inhibitor, is approved for the treatment of human epidermal growth factor receptor 2 (HER2)–negative metastatic breast cancer (MBC) in germline (g)BRCA1/2 mutation carriers. Find out whether the results from this latest report will emphasize the value of molecular characterization (homologous recombination (HR)–related genes other than BRCA1/2) for treatment decisions in MBC.